tesaglitazar has been researched along with captopril in 3 studies
| Studies (tesaglitazar) | Trials (tesaglitazar) | Recent Studies (post-2010) (tesaglitazar) | Studies (captopril) | Trials (captopril) | Recent Studies (post-2010) (captopril) |
|---|---|---|---|---|---|
| 74 | 13 | 25 | 10,320 | 1,514 | 890 |
| Protein | Taxonomy | tesaglitazar (IC50) | captopril (IC50) |
|---|---|---|---|
| Leukotriene A-4 hydrolase | Homo sapiens (human) | 3.6 | |
| Angiotensin-converting enzyme | Homo sapiens (human) | 0.084 | |
| Angiotensin-converting enzyme | Oryctolagus cuniculus (rabbit) | 0.0173 | |
| Succinyl-diaminopimelate desuccinylase | Haemophilus influenzae Rd KW20 | 3.3 | |
| Angiotensin-converting enzyme | Rattus norvegicus (Norway rat) | 0.1004 | |
| Beta-lactamase | Pseudomonas aeruginosa | 5 | |
| Angiotensin-converting enzyme 2 | Homo sapiens (human) | 0.011 | |
| Beta-lactamase class B VIM-2 | Pseudomonas aeruginosa | 3.5 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
3 other study(ies) available for tesaglitazar and captopril
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |